查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595261

消化性溃疡治疗药物市场：依消化性溃疡类型、药物类型、通路划分 - 全球预测 2025-2030

Peptic Ulcer Drugs Market by Peptic Ulcer Type (Duodenal Ulcer, Gastric Ulcer), Drug Type (Cytoprotective Agents, H2 Blockers, Proton Pump Inhibitors (PPIs)), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年消化性溃疡药物市值为45.1亿美元，预计2024年将达到47.3亿美元，复合年增长率为5.19%，到2030年将达到64.3亿美元。

消化性溃疡药物市场包括用于治疗和管理消化性溃疡的药物，消化性溃疡是胃、小肠上部和食道内壁的病变。这些药物包括制酸剂、质子帮浦抑制剂、H2 受体拮抗剂和针对病菌感染的抗生素。消化性溃疡病的广泛流行推动了对这些药物的需求，而生活方式因素、非类固醇消炎剂的使用增加以及病菌感染的流行又加剧了这种疾病。主要用途包括治疗和预防溃疡、减少併发症和促进胃肠健康。药品主要在医院、诊所以及由个人消费者在医生的监督下使用。

主要市场统计
基准年[2023] 45.1亿美元
预测年份 [2024] 47.3亿美元
预测年份 [2030] 64.3亿美元
复合年增长率（%） 5.19%

市场成长是由胃肠道健康意识增强、人口老化以及提高治疗效果的配方进步等因素所推动的。此外，政府医疗保健支出的增加也为市场扩张提供了潜在的机会。为了抓住这些机会，製药公司应专注于探索新型药物递送系统，例如奈米颗粒介导的递送和缓释性，以提高药物疗效并最大限度地减少副作用。此外，针对基因谱量身定制的个人化医疗方法的开发仍然是一个有前途的技术创新领域。

然而，严格的监管要求、专利到期和高昂的药物开发成本等挑战可能会阻碍市场成长。他们也面临市场竞争和长期吸毒潜在副作用的限制。由于消费者对整体疗法的偏好不断增加，创新应着重于减少抗药性、提高幽门螺旋桿菌根除率以及开拓天然和草药化合物空间。总体而言，消化性溃疡治疗药物市场的特点是不断发展的趋势和技术的进步，因此公司策略性地投资于研发并建立联盟以有效地增强其市场地位，利用成长机会至关重要。

市场动态：快速发展的消化性溃疡药物市场的关键市场洞察

消化性溃疡药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 由于老年人口的增加，消化性溃疡的盛行率很高
    • 提高对消化性溃疡的认识和诊断技术的进步
    • 越来越重视以病人为中心的照护和个人化消化性溃疡治疗
  • 市场限制因素
    • 消化性溃疡药物高成本
  • 市场机会
    • 介绍更新、更有效的消化性溃疡治疗方法
    • 远距远端医疗和电子商务平台的采用越来越多
  • 市场挑战
    • 与消化性溃疡药物相关的副作用

波特五力：驾驭消化性溃疡药物市场的策略工具

波特的五力框架是了解消化性溃疡药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解消化性溃疡药物市场的外部影响

外部宏观环境因素在塑造消化性溃疡治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解消化性溃疡治疗药物市场的竞争状况

消化性溃疡药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵消化性溃疡药物市场供应商的绩效评估

FPNV定位矩阵是评估消化性溃疡治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划消化性溃疡药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，消化性溃疡药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着老年人口的增加，消化性溃疡的盛行率也增加
      • 提高对消化性溃疡的认识和诊断技术的进步
      • 越来越重视以病人为中心的照护和个人化消化性溃疡治疗
    • 抑制因素
      • 消化性溃疡药物价格高
    • 机会
      • 介绍更新、更有效的消化性溃疡治疗方法
      • 扩大远距远端医疗和电子商务平台的采用
    • 任务
      • 与消化性溃疡药物相关的不良反应
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依消化性溃疡类型分類的消化性溃疡治疗药物市场

  • 十二指肠溃疡
  • 胃溃疡

第7章：按药物类型分類的消化性溃疡治疗市场

  • 细胞保护剂
  • H2阻断剂
  • 质子帮浦抑制剂 (PPI)

第八章消化性溃疡治疗药物市场：按分销管道

  • 离线
    • 医院
    • 零售药房
  • 在线的

第九章北美和南美消化性溃疡药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太消化性溃疡药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东与非洲消化性溃疡药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • Century Pharmaceuticals Ltd.
  • Daewoong Pharmaceutical Co. LTD.
  • Dr. Reddy's Laboratories Ltd
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Medopharm Pvt Ltd
  • Merck KGaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Pharmanova India Drugs Pvt. Ltd.
  • Redhill Biopharma Ltd
  • Rosemont Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Ulcerex Pharma
  • USAntibiotics
  • Yuhan Corporation
Product Code: MRR-2A0283E25692

The Peptic Ulcer Drugs Market was valued at USD 4.51 billion in 2023, expected to reach USD 4.73 billion in 2024, and is projected to grow at a CAGR of 5.19%, to USD 6.43 billion by 2030.

The market for Peptic Ulcer Drugs encompasses pharmaceuticals designed to treat and manage peptic ulcers, which are open sores in the lining of the stomach, upper small intestine, or esophagus. The scope includes antacids, proton pump inhibitors, H2-receptor antagonists, and antibiotics targeting H. pylori infections, among others. The necessity for these drugs is driven by the widespread prevalence of peptic ulcer disease, which is exacerbated by lifestyle factors, increased use of NSAIDs, and the prevalence of H. pylori infections. Key applications include the treatment and prevention of ulcers, reducing complications, and improving gastrointestinal health. The drugs are mainly used in hospitals, clinics, and by individual consumers under medical guidance.

KEY MARKET STATISTICS
Base Year [2023] USD 4.51 billion
Estimated Year [2024] USD 4.73 billion
Forecast Year [2030] USD 6.43 billion
CAGR (%) 5.19%

Market growth is propelled by factors such as rising awareness around gastrointestinal health, an aging population, and advancements in drug formulations that offer improved therapeutic outcomes. Additionally, the increase in government healthcare expenditure presents potential opportunities for market expansion. To seize these opportunities, pharmaceutical companies should focus on enhancing drug efficacy, minimizing side effects, and exploring novel drug delivery systems, such as nanoparticle-mediated delivery and sustained-release formulations. Moreover, the development of personalized medicine approaches tailored to genetic profiles remains a promising area for innovation.

However, challenges such as stringent regulatory requirements, patent expirations, and the high cost of drug development could hamper market growth. The market also faces limitations posed by a high level of competition and the potential side effects associated with prolonged medication use. Innovation should focus on reducing drug resistance, improving H. pylori eradication rates, and exploring the natural and herbal compound segments due to growing consumer preferences for holistic therapies. Overall, the peptic ulcer drug market is marked by evolving trends and technology advancements, making it essential for companies to strategically invest in R&D and form alliances to effectively enhance market presence and leverage growth opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peptic Ulcer Drugs Market

The Peptic Ulcer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of peptic ulcers with expanding geriatric population
    • Growing awareness about peptic ulcers and advancements in diagnostic techniques
    • Increasing emphasis on patient-centric care and personalized peptic ulcer treatment
  • Market Restraints
    • High cost of peptic ulcer drugs
  • Market Opportunities
    • Introduction of newer and effective peptic ulcer drugs
    • Growing adoption of telemedicine and e-commerce platforms
  • Market Challenges
    • Adverse effects associated with peptic ulcer drugs

Porter's Five Forces: A Strategic Tool for Navigating the Peptic Ulcer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peptic Ulcer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peptic Ulcer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peptic Ulcer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peptic Ulcer Drugs Market

A detailed market share analysis in the Peptic Ulcer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peptic Ulcer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peptic Ulcer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Peptic Ulcer Drugs Market

A strategic analysis of the Peptic Ulcer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Peptic Ulcer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Century Pharmaceuticals Ltd., Daewoong Pharmaceutical Co. LTD., Dr. Reddy's Laboratories Ltd, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Medopharm Pvt Ltd, Merck KGaA, Mylan N.V., Novartis AG, Pfizer Inc., Pharmanova India Drugs Pvt. Ltd., Redhill Biopharma Ltd, Rosemont Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ulcerex Pharma, USAntibiotics, and Yuhan Corporation.

Market Segmentation & Coverage

This research report categorizes the Peptic Ulcer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Peptic Ulcer Type, market is studied across Duodenal Ulcer and Gastric Ulcer.
  • Based on Drug Type, market is studied across Cytoprotective Agents, H2 Blockers, and Proton Pump Inhibitors (PPIs).
  • Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of peptic ulcers with expanding geriatric population
      • 5.1.1.2. Growing awareness about peptic ulcers and advancements in diagnostic techniques
      • 5.1.1.3. Increasing emphasis on patient-centric care and personalized peptic ulcer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of peptic ulcer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of newer and effective peptic ulcer drugs
      • 5.1.3.2. Growing adoption of telemedicine and e-commerce platforms
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with peptic ulcer drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Peptic Ulcer Drugs Market, by Peptic Ulcer Type

  • 6.1. Introduction
  • 6.2. Duodenal Ulcer
  • 6.3. Gastric Ulcer

7. Peptic Ulcer Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Cytoprotective Agents
  • 7.3. H2 Blockers
  • 7.4. Proton Pump Inhibitors (PPIs)

8. Peptic Ulcer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospitals
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Americas Peptic Ulcer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Peptic Ulcer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Peptic Ulcer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AstraZeneca PLC
  • 4. Boehringer Ingelheim International GmbH
  • 5. Cadila Healthcare Ltd.
  • 6. Century Pharmaceuticals Ltd.
  • 7. Daewoong Pharmaceutical Co. LTD.
  • 8. Dr. Reddy's Laboratories Ltd
  • 9. Eisai Co. Ltd.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GlaxoSmithKline PLC
  • 12. Hikma Pharmaceuticals PLC
  • 13. Medopharm Pvt Ltd
  • 14. Merck KGaA
  • 15. Mylan N.V.
  • 16. Novartis AG
  • 17. Pfizer Inc.
  • 18. Pharmanova India Drugs Pvt. Ltd.
  • 19. Redhill Biopharma Ltd
  • 20. Rosemont Pharmaceuticals Limited
  • 21. Takeda Pharmaceutical Company Limited
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. Ulcerex Pharma
  • 24. USAntibiotics
  • 25. Yuhan Corporation

LIST OF FIGURES

  • FIGURE 1. PEPTIC ULCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. PEPTIC ULCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PEPTIC ULCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PEPTIC ULCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PEPTIC ULCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PEPTIC ULCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DUODENAL ULCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GASTRIC ULCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CYTOPROTECTIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS (PPIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY PEPTIC ULCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PEPTIC ULCER DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 188. PEPTIC ULCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. PEPTIC ULCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023